Condition 1: Metabolic, infectious and oxidative complications of coronary artery bypass grafting surgery. Condition 2: Coronary Artery Disease. Infection and inflammatory reaction due to cardiac valve prosthesis, Unspecified complication of cardiac and vascular prosthetic device, implant and graft Atherosclerotic cardiovascular disease, Atherosclerotic heart disease, Chronic ischaemic heart disease, unspecified,
Conditions
Interventions
Intervention 1: group 4: receives placebo (a pack of starch daily) 7 days before and 30 days post surgery. Intervention 2: group 3: receives the supplement (a 20 gram pack of the supplement daily) 7 d
Placebo
Treatment - Drugs
group 4: receives placebo (a pack of starch daily) 7 days before and 30 days post surgery
group 3: receives the supplement (a 20 gram pack of the supplement daily) 7 days before and 30 days post surgery
group 2: receives the placebo (a pack of starch daily) 7 days before surgery and supplement (a 20 gram pack of the supplement daily) 30 days post surgery
group 1: receives the supplement (a 20 gram pack of the supplement daily) 7 days before surgery and placebo (a pack of starch daily) 30 days post surgery
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: male and female patients in the range of 30 to 70 years old, undergoing coronary artery bypass grafting surgery, exclusion criteria: Diabetes mellitus, Metabolic, hematological, and immune disorders, history of renal problem and CVA, taking antioxidant supplements, emergency operations, ejection fraction < 30%
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma glucose level. Timepoint: measured in 5 steps: 1 week before surgery, on the day of surgery before anf after the operation, 1 week after surgery and 1 month after surgery. Method of measurement: spectrophotometric method.;Serum insulin level. Timepoint: measured in 5 steps: 1 week before surgery, on the day of surgery before anf after the operation, 1 week after surgery and 1 month after surgery. Method of measurement: Eliza.;Hemoglobin A1C. Timepoint: measured in 5 steps: 1 week before surgery, on the day of surgery before anf after the operation, 1 week after surgery and 1 month after surgery. Method of measurement: HPLC.;Body composition changes. Timepoint: measured in 4 steps: 1 week before surgery, on the day of surgery, 1 week after surgery and 1 month after surgery. Method of measurement: using Body impedance analyser, skinfold measurement with caliper, and Arm muscle circumference with tape meter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid peroxidatin level. Timepoint: measured in 5 steps: 1 week before surgery, on the day of surgery before anf after the operation, 1 week after surgery and 1 month after surgery. Method of measurement: TBARS method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzieh Akbarzadeh
Shiraz University of Medical Sciences, School of Nutrition and Food Sciences
Outcome results
None listed